The following information has been compiled from publicly available sources,
StratCom does not assume any responsibility for the accuracy or the authenticity
of the information and StratCom cannot be held liable for errors.
Dade Behring granted a non-exclusive license to Abbott Diagnostics for the worldwide rights for the use of placental growth factor (PlGF) for the diagnosis and prognosis of acute coronary syndrome.
Genosis launched Fertell, a home test for male fertility. A sperm sample is added to a device that is designed to mimic a cervix. It indicates if the donor has enough sperm that can swim to fertilize an egg. The test sells for approximately $100. Genosis expects to have Fertell on sale in the U.S., in Continental Europe and Asia by the end of 2006.
Immunicon entered into a supply and marketing license agreement with KREATECH Biotechnology that enables Immunicon to use KREATECH's Universal Linkage System technology in the design of ULS labeled centromere probes for detection circulating cancer cells.
Mitsubishi Kagaku Iatron was granted CE Mark for its Troponin I, creatinine kinase M/B, myoglobin and D-Dimer in-vitro diagnostic assays for the PATHFAST Point-Of-Care analyzer.
NovaScreen Biosciences, a Caliper Life Sciences company launched its KinaseAdvisor screening panel of 48 protein kinase assays. NovaScreen performs the KinaseAdvisor assays on the Caliper LabChip 3000 platform, which uses electrophoresis instead of antibodies as the basis of the assay.
Pathway Diagnostics is using protein signatures to develop in vitro diagnostic tests and laboratory services for chronic obstructive pulmonary disease (COPD) and inflammatory bowel disorder (IBD).
Roche Diagnostics was granted CE Mark for its LightCycler SeptiFast test developed in collaboration with Innogenetics. Roche stated it hopes the test will replace current diagnosis based on blood cultures.